Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Prudence and promise in psychedelic-assisted therapy

Charles Saylor and Jacob M. Appel, MD, JD, MPH
Meds
November 30, 2022
Share
Tweet
Share

Psychedelic-assisted therapy (PAT) represents one of the most promising developments in psychiatry in decades. The treatment typically involves the infusion of a compound such as LSD, psilocybin, or MDMA during an extended therapy session with licensed professionals.

Although it lacks widespread regulatory approval or clinical use, significant advances have been made in the study of PAT in the past decade, with a pronounced increase in recent years. Recently, a study published in the New England Journal of Medicine demonstrated that a single 25mg dose of psilocybin (the active compound in psychedelic mushrooms) accompanied by psychotherapy was effective in reducing symptoms in patients with treatment-resistant depression, a condition that is notoriously difficult to treat.

This study is the most recent example in a pattern of trials demonstrating PAT’s efficacy for everything from PTSD to alcohol use disorder. However, the field dates to the mid-20th century, when doctors conducted studies that, despite poor design, used the exact same compounds (e.g., LSD) for very similar psychiatric conditions (e.g., alcohol use disorder). This initial groundswell of research in the 50s and 60s was doomed by political and social forces in the United States that halted funding and led to a decades-long hiatus, of which the field has only recently emerged.

Its resurgence is also steeped in controversy. Valid criticism has been levied against clinical trials which use consciousness-altering medications that are difficult (or impossible) to control for with placebo. In contrast to most large placebo-controlled clinical trials, many trials of PAT have pathetic blinding results, with over 90 percent of participants correctly guessing whether they received active medication or placebo. This muddies the waters of the analysis and makes it difficult to attribute results to the treatment, the placebo, or both. The NEJM study didn’t bother with placebo and instead used lower doses of psilocybin as comparators – patients who got the lower doses had less of a response.

These studies can also be subject to expectancy effects. Just as a jury may be inadvertently swayed by press coverage or social media, patients who are familiar with the tremendous promise or “hype” surrounding PAT may be more likely to believe the treatment works and thus respond positively to the intervention.

There is also a discrepancy between the public understanding of PAT and the actual state of the field. Microdosing, which some claim will boost creativity, and productivity or treat psychiatric conditions, is unrelated to PAT and largely lacks evidence of its validity. Ketamine, which is widely used for psychiatric indications, is another unrelated entity: it is not structurally related to classical psychedelics, nor is it typically administered during therapy sessions.

Also, PAT is a synthesis of both therapy and medication. Dosing typically involves an infusion that is administered during a monitored therapy session, not picked up from a pharmacy. This is in stark contrast to the distribution of other sensitive medications like opioids or Adderall, but many fail to recognize the difference.

Also, there have been very few trials of PAT that adequately reflect the racial or ethnic makeup of the United States. Many groundbreaking studies have recruited mostly white participants, limiting the generalizability of any findings. The NEJM paper was no different — more than 90 percent of the participants were white. The therapy session/infusion is also a prolonged process, which can take many hours, making it difficult for many people to access these treatments. If you cannot reasonably take a day off from work, how could you expect to attend multiple 8-hour treatment sessions?

Finally, PAT has begun to take on the appearance of a silver bullet, which can treat a wide range of conditions that may not have similar pathological mechanisms. This should give pause to many clinicians and regulators; new therapies are often touted as being more effective than they really are. If expectations are inflated beyond reality, it will endanger what may be a valid and effective tool in the arsenal of our country’s psychiatrists.

The United States is in a crisis of mental health care. As psychiatrists, we are keenly aware of the urgent need for novel interventions for conditions ranging from PTSD to cigarette addiction to depression. Many millions of people may be safely and effectively treated by PAT, and regulatory approval or rejection of PAT could be imminent. However, the accelerating excitement surrounding PAT threatens to endanger the cause itself. While recent results have been exciting, and there is plenty of work ahead of us, and the best path forward is a measured, cautious approach that also allows for the safest and most evidence-based therapies to reach the largest number of people.

Charles Saylor is a medical student. Jacob M. Appel is a psychiatrist.

Image credit: Shutterstock.com

Prev

A doctor's grief

November 30, 2022 Kevin 2
…
Next

Effective doctors need to be challenged [PODCAST]

November 30, 2022 Kevin 0
…

ADVERTISEMENT

Tagged as: Psychiatry

Post navigation

< Previous Post
A doctor's grief
Next Post >
Effective doctors need to be challenged [PODCAST]

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

Related Posts

  • Stop stigmatizing medication-assisted treatment

    Brandon Jacobi
  • What doctors need to know about psychedelic medicine

    Lynn Marie Morski, MD, JD
  • Hormone replacement therapy is still linked to cancer

    Martha Rosenberg
  • Art therapy and the intersection between chronic illness and mental health

    Amy Oestreicher
  • America’s prescription epidemic: Breaking an ancient promise

    Jesse Seilern und Aspang, MD, Riana Patel, MD and Mara Schenker, MD
  • Medicare for all: a campaign promise, catchy bumper sticker, or viable program?

    Bonnie Friedman

More in Meds

  • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

    Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO
  • A world without antidepressants: What could possibly go wrong?

    Tomi Mitchell, MD
  • The truth about GLP-1 medications for weight loss: What every patient should know

    Nisha Kuruvadi, DO
  • The hidden bias in how we treat chronic pain

    Richard A. Lawhern, PhD
  • Biologics are not small molecules: the case for pre-allergy testing in an era of immune-based therapies

    Robert Trent
  • The anesthesia spectrum: Guiding patients through comfort options in oral surgery

    Dexter Mattox, MD, DMD
  • Most Popular

  • Past Week

    • The silent toll of ICE raids on U.S. patient care

      Carlin Lockwood | Policy
    • Why recovery after illness demands dignity, not suspicion

      Trisza Leann Ray, DO | Physician
    • Addressing the physician shortage: How AI can help, not replace

      Amelia Mercado | Tech
    • Bureaucracy over care: How the U.S. health care system lost its way

      Kayvan Haddadan, MD | Physician
    • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

      Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO | Meds
    • Why medical students are trading empathy for publications

      Vijay Rajput, MD | Education
  • Past 6 Months

    • What’s driving medical students away from primary care?

      ​​Vineeth Amba, MPH, Archita Goyal, and Wayne Altman, MD | Education
    • Residency as rehearsal: the new pediatric hospitalist fellowship requirement scam

      Anonymous | Physician
    • The broken health care system doesn’t have to break you

      Jessie Mahoney, MD | Physician
    • Make cognitive testing as routine as a blood pressure check

      Joshua Baker and James Jackson, PsyD | Conditions
    • A faster path to becoming a doctor is possible—here’s how

      Ankit Jain | Education
    • The hidden bias in how we treat chronic pain

      Richard A. Lawhern, PhD | Meds
  • Recent Posts

    • When errors of nature are treated as medical negligence

      Howard Smith, MD | Physician
    • Physician job change: Navigating your 457 plan and avoiding tax traps [PODCAST]

      The Podcast by KevinMD | Podcast
    • The hidden chains holding doctors back

      Neil Baum, MD | Physician
    • Hope is the lifeline: a deeper look into transplant care

      Judith Eguzoikpe, MD, MPH | Conditions
    • Why medical students are trading empathy for publications

      Vijay Rajput, MD | Education
    • From hospital bed to harsh truths: a writer’s unexpected journey

      Raymond Abbott | Conditions

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • The silent toll of ICE raids on U.S. patient care

      Carlin Lockwood | Policy
    • Why recovery after illness demands dignity, not suspicion

      Trisza Leann Ray, DO | Physician
    • Addressing the physician shortage: How AI can help, not replace

      Amelia Mercado | Tech
    • Bureaucracy over care: How the U.S. health care system lost its way

      Kayvan Haddadan, MD | Physician
    • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

      Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO | Meds
    • Why medical students are trading empathy for publications

      Vijay Rajput, MD | Education
  • Past 6 Months

    • What’s driving medical students away from primary care?

      ​​Vineeth Amba, MPH, Archita Goyal, and Wayne Altman, MD | Education
    • Residency as rehearsal: the new pediatric hospitalist fellowship requirement scam

      Anonymous | Physician
    • The broken health care system doesn’t have to break you

      Jessie Mahoney, MD | Physician
    • Make cognitive testing as routine as a blood pressure check

      Joshua Baker and James Jackson, PsyD | Conditions
    • A faster path to becoming a doctor is possible—here’s how

      Ankit Jain | Education
    • The hidden bias in how we treat chronic pain

      Richard A. Lawhern, PhD | Meds
  • Recent Posts

    • When errors of nature are treated as medical negligence

      Howard Smith, MD | Physician
    • Physician job change: Navigating your 457 plan and avoiding tax traps [PODCAST]

      The Podcast by KevinMD | Podcast
    • The hidden chains holding doctors back

      Neil Baum, MD | Physician
    • Hope is the lifeline: a deeper look into transplant care

      Judith Eguzoikpe, MD, MPH | Conditions
    • Why medical students are trading empathy for publications

      Vijay Rajput, MD | Education
    • From hospital bed to harsh truths: a writer’s unexpected journey

      Raymond Abbott | Conditions

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Prudence and promise in psychedelic-assisted therapy
1 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...